[A case report of anti-NMDA receptor encephalitis with mental disturbances manifestation].

Presented clinical observation of anti-NMDA-receptor encephalitis, which was first described in 2007, is rare and to date has not been sufficiently studied. The disease often manifests with psychopathological symptoms and catatonia, so patients are transferred into a mental healthcare institution and often require intensive care and resuscitation, due to the development of life-threatening respiratory and hemodynamic disorders. Diagnosis is based on detection of autoantibodies to the NR1- and NR2 subunits of the glutamate NMDA receptor in blood serum and cerebrospinal fluid.

[New opportunities in the treatment of patients with multiple sclerosis (Resolution of the Council of Experts on April 23, 2022, Moscow, JSC «BIOCAD»)].

One of the target areas for the development of the Russian pharmaceutical industry at present is the development of next-in-class drugs medicines. These are original, patent-protected drugs that act on known biological targets, improved or modified in structure and mechanism of action compared to existing, successfully proven medicine. The article presents the results of an expert council on the management of patients with multiple sclerosis and the place of new original medicines of the JSC BIOCAD company (SamPEG-IFN-β1a and divozilimab) in multiple sclerosis therapy algorithm.

[Application of modern approaches in the screening and early diagnosis programs for the orphan diseases].

Orphan diseases have a prevalence ranging one patient per 10.000 population in the Russian Federation to one per 1500-2000 individuals in Australia and the USA. Many orphan diseases lead to a severe decrease in quality of life and high mortality.

[Spinal muscular atrophy in samara region. Epidemiology, classification, prospects for health care].

The paper addresses the problem of spinal muscular atrophy in Russia, in particular in Samara region. There are 58 alive patients, including 19 children, registered to June 2019 in the Samara Regional Clinical Hospital n.a.

[The organization of diet therapy from positions of development of patient-oriented health care].

The article discusses the problematic issues of the organization of medical nutrition of sick people both in medical organizations and outside of their stay, reflecting the current understanding of the organization of therapeutic nutrition as the main structural element of the patient-oriented health care system. The authors declare the need for an evidence-based assessment of the effectiveness of personalized diet therapy and the use of specialized enrichment of patients 'diet. The article presents the rationale for the correctness of using for this purpose a proven methodology for assessing the effectiveness of alternative technologies in healthcare.

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].

Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab. This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy.

[Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists].

The main results of a medical-sociological study aimed at the evaluation of the level of satisfaction with treatment in patients with primary progressive multiple sclerosis (PPMS) are presented. The survey was conducted in 19 regions of the Russian Federation and involved 437 patients with confirmed diagnosis of PPMS and 80 neurologists specialized in multiple sclerosis. The research was carried out by the All-Russian Public Organization of Disabled People with Multiple Sclerosis with the participation of the Russian Committee for Treatment and Research in Multiple Sclerosis.

[Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis].

Multiple sclerosis is a chronic demyelinating and neurodegenerative disease of the central nervous system, in which autoimmune inflammation and oxidative stress play essential pathogenetic roles. Activation and infiltration of immune cells in brain tissues, lipid peroxidation products, mitochondrial dysfunction, defective antioxidant protection, and many other pathological factors result in demyelination, axonal injury and death, and apoptosis of oligodendrocytes and neurons, all of which causes constant progression of the disease. The new oral agent for the treatment of relapsing-remitting multiple sclerosis (RRMS), dimethyl fumarate (DMF), helps change the pathogenetic mechanisms of the disease, thus decreasing the rate of exacerbations, slowing down disease progression, and reducing the risk of radiological progression of the disease.

[Substantiation of increasing the quality of disease-modifying therapy for multiple sclerosis using in the Russian Federation].

The problems of using disease-modifying drugs in treatment of multiple sclerosis related to the difficulties of the control over the quality of bioanalogues imported into or manufactured in the Russian Federation are discussed.

[The early diagnosis of neurodegenerative changes in multiple sclerosis and clinically isolated syndrome based on optical coherence tomography of the retina].

Aim: To study signs of neurodegeneration in the retina in multiple sclerosis.

Material And Methods: We studied the retinal nerve fiber layer (RNFL) in 265 (524 eyes) patients.

Results And Conclusion: We identified a reliable thinning of RNFL of both eyes in patients with relapsing-remitting multiple sclerosis (MS).